Latest News

John H. Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and professor of psychiatry, of neuroscience, and of psychology, and chair of the Yale Department of Psychiatry; and Christopher Pittenger, MD, PhD, Elizabeth Mears and House Jameson Professor of Psychiatry, were among six psychiatric researchers, entrepreneurs, and healthcare industry professionals who participated in a panel during the 10th annual Yale Innovation Summit on May 30. The panel was titled "Biotech: Exploring The Psychedelic Renaissance."

Thirteen members of the Yale School of Medicine (YSM) and Yale School of Public Health (YSPH) faculties have been elected to the Connecticut Academy of Science and Engineering (CASE). In all, 35 of Connecticut’s leading experts in science, technology, engineering, mathematics, and medicine were elected this year.

Hilary Blumberg, MD; Kelly Cosgrove, PhD; and Christopher Pittenger, MD, PhD, have been elected to membership in the Connecticut Academy of Science & Engineering.

Christopher Pittenger, MD, PhD, Elizabeth Mears and House Jameson Professor of Psychiatry, spoke to Everyday Health about clinical treatments involving psilocybin therapy.

Two Yale Department of Psychiatry scientists have been awarded a federal research grant to study the effects of the drugs MDMA and methylone as possible treatments for veterans with post-traumatic stress disorder (PTSD).

Elm City COMPASS of New Haven was honored with the Yale Department of Psychiatry's Mental Health Advocacy Award at the 2023 Yale-NAMI Conference on Neuroscience and Mental Health held May 13 at The Anlyan Center.

Enock Teefe, MD, from the laboratory of Thomas Fernandez, MD, and co-mentored by Christopher Pittenger, MD, PhD, and José Jaime Martínez-Magaña, PhD, from the laboratory of Janitza Montalvo-Ortiz, PhD, have been selected to receive the 2023 Kavli Postdoctoral Award for Academic Diversity.

Christopher Pittenger, MD, PhD, Elizabeth Mears and House Jameson Professor of Psychiatry, spoke to National Geographic about the possibilities that psychedelic medicines can benefit people with depression, addiction, and other common disorders.

In late August, a JAMA Psychiatry article detailed the results of the largest-ever clinical trial of a drug called psilocybin, a psychedelic found in so-called “magic mushrooms.” The study found that a combination of psilocybin and talk therapy reduced drinking by 80% after eight months of therapy. To talk about this, Dr. Christopher Pittenger, a Yale School of Medicine professor and director of the Yale OCD Research Clinic, joined "All Things Considered." He says he’s not only encouraged by the study, but also by the interest Connecticut legislators have shown in one day making psilocybin therapy available to people it could help.